Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Owlstone Medical, a global diagnostics company developing a breathalyser for applications in early disease detection and precision medicine, has formed a partnership with the International Association of Heat and Frost Insulators and Allied Workers (IAHFIAW), formerly known as the Asbestos Workers, a building trades union in the US and Canada, to identify and verify breath-based biomarkers for the early detection of malignant mesothelioma.

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

The partnership between Owlstone Medical and the Heat and Frost Insulators aims to address the need for early detection by using Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma. The project will be divided into two phases and is expected to run for 3 years. It will be financially supported by Heat and Frost Insulators’ Tissue Bank Asbestos Research Charitable Trust nonprofit. The first phase, approved on April 24, will focus on identifying volatile organic compounds (VOCs) found in the breath of individuals diagnosed with malignant mesothelioma.

The second phase will be a blind study to verify the sensitivity, specificity and positive and negative predictive values of selected VOC biomarkers identified in the first phase. Breath samples will be collected using Owlstone Medical’s ReCIVA Breath Sampler and will be analyzed by their state-of-the-art Breath Biopsy laboratory in Cambridge, UK. The study will be led by Principal Investigator Dr. Michael R. Harbut, and co-Investigator Dr. David Svinarich, Ascension Healthcare's2 Vice President of Research.

Malignant mesothelioma is a rare, aggressive and treatment-resistant disease caused almost exclusively by exposure to asbestos and asbestiform fibers. Early detection of the disease is highly challenging, as a long latency period of 40-50 years between first asbestos exposure and disease onset is typical, and symptoms, when present, may be non-specific. As a result, patient prognosis is poor, with a median survival of nine to 12 months from diagnosis.

Although the disease is not common (3,200 new cases3 per year in the USA), the at-risk population is substantial with more than 100 million people in the U.S. alone having been exposed to asbestos fibers and a further 1.3 million4 American workers in the construction and general industry alone exposed to asbestos on the job each year.

The identification of individuals among this population who are either predisposed to developing malignant mesothelioma, or who already have early disease stage, would likely dramatically improve prognosis by limiting disease progression through earlier therapeutic interventions. Unfortunately, due to the perceived rarity of malignant mesothelioma, little research has been conducted to date on either the early identification or treatment of individuals with disease.

James P. McCourt, General President, IAHFIAW commented: “The population of those who have been exposed to asbestos and are at risk of having existing early-stage disease or developing malignant mesothelioma later in their lives includes a substantial portion of our membership. The long-term health of our members is of primary importance to the IAHFIAW, and we are confident that our partnership with Owlstone Medical will provide significant advances in the early diagnosis of this disease.”

Michael R. Harbut, MD, MPH; Clinical Professor of Internal Medicine at Wayne State University School of Medicine and Michigan State University College of Human Medicine, and medical advisor to the IAHFIAW, said: “The diagnosis of malignant mesothelioma is typically very late in the course of the disease when surgery is not viable owing to its proliferation, and the cancer is less responsive to chemotherapy. To change this, reliable diagnostic tests that enable the earlier detection of malignant mesothelioma in at-risk populations are badly needed.”

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Malignant mesothelioma is a powerful example of an unaddressed medical need where Breath Biopsy has the potential to make a substantial difference. Through this partnership, we are looking not only to advance the early diagnosis of malignant mesothelioma, but also to demonstrate that breath-based screening has the potential to have a substantial impact on a wide range of environment-driven disease.”

Read More

Related news

New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

13 Dec 2019

NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.

Read more 
Sanofi bolsters its immuno-oncology pipeline for $2.5B

Sanofi bolsters its immuno-oncology pipeline for $2.5B

6 Dec 2019

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Read more 
Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more 
Eli Lilly unveils shared innovation laboratory in San Francisco

Eli Lilly unveils shared innovation laboratory in San Francisco

3 Dec 2019

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Read more 
Ground-breaking work creates novel oil-in-water nanoemulsions

Ground-breaking work creates novel oil-in-water nanoemulsions

3 Dec 2019

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Read more 
UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
Recipharm joins the AMR Industry Alliance

Recipharm joins the AMR Industry Alliance

15 Nov 2019

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

Read more